Back to Trials
NCT07492927Recruiting

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Xijing Hospital

Start Date

3/12/2021

Completion Date

6/30/2027

Summary

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Blood prostate-specific antigen PSA\>4ng/dl; 2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging. 3. The patient is willing to undergo prostate biopsy. Exclusion Criteria: 1. Previous diagnosis of prostate cancer through prostate biopsy; 2. History of other malignant tumors in the past two years; 3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Clinically Significant Prostate Cancer

Locations

Northwestern Memorial Hospital

Chicago, Illinois 60611

United States

The First Hospital of Lanzhou University

Lanzhou, Gansu

China

General Hospital of Ningxia Medical University

Yinchuan, Ningxia

China

Qinghai University Affiliated Hospital

Xining, Qinghai

China

Weinan Central Hospital

Weinan, Shaanxi

China

Shaanxi Provincial People's Hospital

Xi'an, Shaanxi

China

Xijing 986 Hospital

Xi'an, Shaanxi

China

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

Xianyang, Shaanxi

China

Yan'an University Affiliated Hospital

Yan’an, Shaanxi

China

Xijing Hospital

Xi'an, 710032

China